Author

T. V. Plaksina

Observed names: T Plaksina, T. Plaksina, Tatyana Plaksina, Плаксина Т. В., Плаксина Т.В., Т. В. Плаксина

Institution: Nizhny Novgorod Regional Clinical Hospital named after Semashko

Observed institutions: Sechenov University, Nizhny Novgorod Regional Clinical Hospital named after Semashko

ORCID: 0000-0002-6927-1752

Observed ORCID: 0000-0002-6927-1752

OpenAlex ID: A5110592203

The Results of a Phase Iii Comparative Clinical Trial of Rituximab (acellbia® and Mabthera®) in Rheumatoid Arthritis (the Biora Study)

2016 · E. L. Nasonov, E. V. Zonova, et al. · Rheumatology Science and Practice · 35

Efficacy and safety of netakimab, anti-IL-17A monoclonal antibody, in patients with ankylosing spondylitis. Results of phase III international, multicenter, randomized double-blind clinical trial BCD-085-5/ASTERA

2020 · V. I. Mazurov, I. Z. Gaydukova, et al. · Rheumatology Science and Practice · 19

PDF

Effectiveness and safety of BCD180, anti-TRBV9+ T-lymphocytes monoclonal antibody in patients with active radiographic axial spondyloarthritis: 36-week results of double-blind randomized placebo-controlled phase II clinical study ELEFTA

2024 · E. L. Nasonov, V. I. Mazurov, et al. · Rheumatology Science and Practice · 18

PDF

Efficacy and safety of levilimab in combination with methotrexate in subjects with rheumatoid arthritis: Results of phase II AURORA study

2021 · V. I. Mazurov, E. G. Zotkin, et al. · Rheumatology Science and Practice · 18

PDF

Long-term efficacy and safety of netakimab in the treatment of ankylosing spondylitis: results of Phase III international, multicenter, randomized double-blind clinical trial BCD-085-5/ASTERA

2020 · V. I. Mazurov, Sh. F. Erdes, et al. · Modern Rheumatology Journal · 17

PDF

The Efficacy and Safety of BCD-180, an Anti-TRBV9+ T cell Monoclonal Antibody, in Patients with Active Radiographic Axial Spondyloarthritis: 36-week Results from the Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study ELEFTA

2025 · E. L. Nasonov, V. I. Mazurov, et al. · Doklady Biochemistry and Biophysics · 16

Effectiveness and safety of levilimab in combination with methotrexate in treatment of patients with active rheumatoid arthritis resistant to methotrexate monotherapy (double-blinded randomized placebo controlled phase III clinical study SOLAR)

2021 · V. I. Mazurov, M. A. Korolev, et al. · Modern Rheumatology Journal · 14

PDF

The Efficacy and Safety of Rituximab Biosimilar (acellbia®) in Rheumatoid Arthritis as the First Biological Agent: Results of Phase Iii (alterra) Clinical Trial

2017 · E. L. Nasonov, V. I. Mazurov, et al. · Rheumatology Science and Practice · 13

Long-term efficacy and safety of netakimab in patients with active ankylosing spondylitis: results of three years of use in the international multicentre, randomized, double-blind, phase III clinical trial BCD-085-5/ASTERA

2024 · V. I. Mazurov, Sh. F. Erdes, et al. · Modern Rheumatology Journal · 9

PDF

Comparative efficacy and safety of infliximab biosimilar (BCD-055) and innovator infliximab in patients with ankylosing spondylitis (results of international, multiple-center, double-blind phase I and phase III clinical studies)

2017 · D. E. Karateev, V. I. Mazurov, et al. · Modern Rheumatology Journal · 6

PDF

Use of olokizumab, a direct interleukin 6 inhibitor, in the treatment of rheumatoid arthritis: real-world evidence

2025 · P. A. Shesternya, A. I. Zagrebneva, et al. · Modern Rheumatology Journal · 5

PDF

Efficacy and Safety of Levilimab in Combination with Methotrexate in Patients with Active Rheumatoid Arthritis: 56-Week Results of Phase III Randomized Double-Blind Placebo-Controlled Trial SOLAR

2024 · V. I. Mazurov, E. L. Nasonov, et al. · Doklady Biochemistry and Biophysics · 5

Efficacy and safety of levilimab in combination with methotrexate in patients with active rheumatoid arthritis: 56-week results of phase III randomized double-blind placebo-controlled trial SOLAR

2023 · V. I. Mazurov, A. M. Lila, et al. · Rheumatology Science and Practice · 5

PDF

Efficacy and safety of levilimab in the treatment of rheumatoid arthritis in real-life clinical practice: first results of the HELIOS observational study

2024 · A. M. Lila, I. Z. Gaydukova, et al. · Modern Rheumatology Journal · 4

Fri0114 Efficacy of Levilimab, Novel Monoclonal Anti-il-6 Receptor Antibody, in Combination With Methotrexate in Patients With Rheumatoid Arthritis: 1-year Results of Phase 2 Aurora Study

2020 · V. Mazurov, E. Zotkin, et al. · Annals of the Rheumatic Diseases · 4

PDF

Efficacy and safety of a new original interleukin 17A inhibitor in the treatment of patients with active ankylosing spondylitis: results of a basic (BCD-085-3/AILAS) and extended (BCD-085-3ext/AILAS-II) phase II clinical trial

2019 · Sh. Erdes, V. I. Mazurov, et al. · Rheumatology Science and Practice · 4

PDF

Fri0108 Short-term Efficacy of Bcd-089, Novel Monoclonal Anti-il-6 Receptor Antibody, in Combination With Methotrexate in Patients With Rheumatoid Arthritis: 12-week Results of Phase 2 Aurora Study

2019 · V Mazurov, Evgeniy Zotkin, et al. · Annals of the Rheumatic Diseases · 4

PDF

Op0232 Netakimab Reduces the Disease Activity of Radiographic Axial Spondyloarthritis. Results of Astera Study

2019 · Inna Gaydukova, V Mazurov, et al. · Annals of the Rheumatic Diseases · 4

PDF

The Efficacy and Safety of Divozilimab in Patient with Systemic Sclerosis: 48-Week Results of the Randomized Double-Blind Placebo-Controlled Phase III Clinical Study LIBERIUS

2025 · L. P. Ananyeva, M. N. Starovoytova, et al. · Doklady Biochemistry and Biophysics · 3

PDF

Pos0624 Efficacy and Safety of Levilimab in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis: Phase Iii, Double-blind, Placebo-controlled, Randomized Trial

2021 · V. Mazurov, M. Korolev, et al. · Annals of the Rheumatic Diseases · 3

PDF

Comparative Evaluation of the Long-term Efficacy and Safety of the Infliximab Biosimilar Bcd-055 and Reference Infliximab in Patients With Ankylosing Spondylitis: Results of the International Multicenter Randomized Double-blind Phase Iii Clinical Study Asart-2

2018 · A. M. Lila, V. I. Mazurov, et al. · Rheumatology Science and Practice · 3

Direct interleukin-6 blockade in real-world clinical practice – a path to rationalization of pharmacotherapy and control of rheumatoid arthritis

2026 · P. A. Shesternya, E. M. Aitova, et al. · Modern Rheumatology Journal · 2

PDF

Long-term effects of netakimab on health-related quality of life, back pain and work productivity in patients with ankylosing spondylitis: results of the international, multicentre, randomized double-blind phase III clinical trial BCD-085-5/ASTERA

2023 · T. V. Dubinina, A. B. Demina, et al. · Modern Rheumatology Journal · 2

PDF

THU0193 Efficacy and safety of bcd-055 (INFLIXIMAB BIOSIMILAR) in rheumatoid arthritis. results of bcd-055–3/lira phase 3 clinical study

2018 · A. Lila, L. Denisov, et al. · Annals of the Rheumatic Diseases · 2

PDF

FRI0208 Comparison of efficacy, safety and pharmacokinetics of infliximab biosimilar (BCD-055) and innovator infliximab

2017 · L Denisov, I Gordeev, et al. · Annals of the Rheumatic Diseases · 2

PDF

Works count: 40

Citation count: 221

H-index: 9

I10-index: 8